Dr. Raj Mohanty is a founder of FemtoDx. Among his numerous work experiences, he has served as a researcher at NASA, Goddard Space Flight Center and California Institute of Technology, and a faculty member at Boston University. He is the recipient of the NSF Career Award and Sloan Fellowship. He has published over 80 research articles in peer-reviewed journals such as Nature, Science and Physical Review Letters. He holds a PhD in quantum physics from University of Maryland. Prior to founding FemtoDx, Dr. Mohanty was the founder and the first CEO of Sand 9, a semiconductor chip company that went on to raise around $70 million and was acquired by Analog Devices (NASDAQ: ADI). Dr. Mohanty now serves as a board member or as an adviser at multiple companies in the technology and media space.

Dr. Patrick Anquetil is the founder and CEO of Portal Instruments. Patrick brings more than 18 years of experience leading high-tech bioengineering companies from the lab to the market place and building world-class teams. Prior to founding Portal Instruments, from 2009 to 2012, he was co-founder and director of strategic planning for SynapDx Corporation, where he had responsibility for development of the company's business and operational plans as well as securing Series A funding. SynapDx went on to raise more than $40 million in venture capital to develop the first test to detect the early onset of autism using technologies licensed exclusively from Boston Children's Hospital and George Washington University. He also co-founded Aretais, Inc. to develop a non-invasive method to detect blood glucose using Coherent Anti-Stokes Raman Spectroscopy (CARS) backed by Pfizer, Inc. Patrick began his career as a science and nanotechnology equity research analyst at Susquehanna International Group, authoring and marketing industry and equity research reports to hedge funds and portfolio managers. Patrick holds a doctorate in BioInstrumentation from MIT, an MBA from Harvard University, and a master's degree from the ETH in Zurich and the University of Tokyo. His scientific work has appeared in numerous peer-reviewed publications as well as mainstream media, including MIT Technology Review, Wired Magazine, PBS, and CNBC among others.

Rahul is an executive director at Baldota Group, a conglomeration of companies in mining, aviation, shipping, wind energy and environmental solutions. Since joining the group in 1993, he has led the accelerated growth by making the mining portfolio company the largest exporter of high-grade iron ore. He has been playing an active role in the apex mining trade body of the country – the Federation of Indian Mineral Industries (FIMI). He served as the President of FIMI from 2007 to 2009. An equally passionate advocate of renewable energy, Rahul leads the effort both as a renewable-energy investor and entrepreneur with multiple projects totaling a net output of over 217 megawatt of power. Rahul holds a Bachelor’s Degree in Production Engineering and has completed his Masters in Business Administration from the University of Illinois, Chicago.

Dr. John Du oversees device engineering development and manages silicon sensor fabrication at Global Foundries. Dr. Du received his PhD in electrical engineering at Case Western University and postdoctoral fellow at California Institute of Technology. Dr. Du has over 15 years of experience in working in medical device industry.

Stan Lapidus is an executive and founder with over three decades of experience in the medical diagnostics space. He is the lead independent board member at T2 Biosystems (NASDAQ: TTOO), a diagnostics company. Stan was the founder and CEO of SynapDx, an autism diagnostics company; Helicos Biosciences (NASDAQ: HLCS), a life sciences company; EXACT sciences (NASDAQ: EXAS), a colorectal cancer diagnostics company; CYTYC (NYSE: CYTC), a cervical cancer diagnostics company. Stan holds academic appointments at MIT and a fellowship at American Institute of Medical and Biomedical Engineering. Stan holds an engineering degree from Cooper Union College.

Dr Shyam Erramilli is a founder of FemtoDx. Dr Erramilli is a professor of biomedical engineering, physics and photonics at Boston University. Prior to joining Boston University, he was a faculty member in the physics department at Princeton University. He was also a visiting professor in physics at Stanford University, and in the Department of Applied Mathematics and Theoretical Physics at Cambridge University. His research is in the field of biological physics, focusing on femtosecond laser spectroscopy and nanoscale physics in biological systems. His research group utilizes plasmonics and metamaterials in the infrared region of the spectrum to study fast reactions in proteins. He is interested in fundamental questions regarding why the dynamics of proteins occur on femtosecond timescales. He is a member of the editorial board of the Journal of Biological Physics, a Springer-Verlag journal. He is the recipient of the duPont Young Professor award, and has served on numerous review panels for the Department of Defense for Breast and Ovarian Cancer, the National Science Foundation and the Nanotechnology panel at the National Institutes of Health. He received his PhD from the University of Illinois at Urbana-Champaign.

Dr. Weaver is the Chief Scientific Officer at FemtoDx. Previously, he was the Vice President of Translational Medicine at Verastem (NASDAQ: VSTM), a biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Dr. Weaver was the Chief Scientific Officer at Ninth Sense, a point-of-care diagnostics company, and the Chief Scientific Officer at On-Q-ity, a cancer diagnostics company commercializing medical devices for tumor cell monitoring and biomarker platforms for patient stratification and treatment. Dr. Weaver is an experienced biotechnology and pharmaceuticals executive having led drug discovery and diagnostics organizations, a fruitful academic career, and including serving on the advisory boards of several organizations supporting drug discovery and global health initiatives. Dr. Weaver was previously a Founder and Chief Scientific Officer of DNAR, concentrating on developing DNA repair pathways in personalized medicine and drug discovery. Dr. Weaver is also the Founder of Akanas Therapeutics providing a novel humanization technology for rapid development of therapeutic antibodies with improved clinical features. David served as Head of Biology R&D at Daiamed, a drug discovery company that delivered protein structure-guided novel small molecule modulators in thrombosis, rheumatoid arthritis, multiple sclerosis, and metabolic disease indications. Previous to a career in biotechnology and pharmaceuticals, Dr. Weaver was an Associate Professor at Harvard Medical School in cancer biology and immunology with laboratories at the Immune Disease Institute and the Dana-Farber Cancer Institute. Dr. Weaver’s research included discoveries of important genome stability pathways including DNA damage responses, DNA repair, and signaling, as well as the genetic and molecular foundation of numerous human pre-cancer and immunodeficiency syndromes. Dr. Weaver received postgraduate training at MIT and the Whitehead Institute with Nobel laureate David Baltimore where he discovered fundamental lymphoid regulatory processes in animal models of human disease. David received a Ph.D. in Biological Chemistry from Harvard for his work on tumor viruses, and a B.S. in Chemistry from the University of Wisconsin.

Carla has twenty five years of experience in medical device quality, regulatory and clinical affairs. She is a Vice President of Quality and Regulatory at Portal Instruments. She has spent her career conceptualizing and implementing global quality and regulatory strategies while balancing business needs with compliance risks. Strategically utilizing her background as a critical care nurse, educator and software developer she uniquely facilitates communication and understanding between medical device manufacturers, their customers and regulators. Carla has held senior management positions in quality, regulatory and clinical in start-up and large corporate settings such as SynapDx, an early stage diagnostics company, Johnson & Johnson's DePuy Mitek business; Edwards Lifesciences' Critical Care and Cardiac Surgery businesses; Philips Home Healthcare Solutions; Bard Electrophysiology and Boston Scientific. Carla received her Masters in Computer Science from Fitchburg State University and her BS in Nursing from the University of California, San Francisco.

Hiroo D. Awano works on corporate development and strategic partnership with a special focus on Japan. He is also the Managing Director of Herakles Capital International Corporation based in New York. He has over 25 years global investment banking experience both at Merrill Lynch & Co. and Salomon Brothers in New York, focusing on international transactions, with a specialty in energy and power. Hiroo has been working on In-Vitro Diagnostics projects for over 12 years, starting with his work on the IP portfolio generated by the research work of Nobel Laureate Dr. Shinya Yamanaka of Kyoto University. He was at McKinsey's New York and Tokyo offices for eight years after graduating from Stanford University with an MBA.

Dr. Steinhubl is the Director of Digital Medicine at STSI and a cardiologist at Scripps Health, Scripps Clinic. He received his undergraduate training in chemical engineering at Purdue University in Indiana, graduate training in physiology at Georgetown University in Washington, DC, and his medical degree at St. Louis University in Missouri. Steve’s internal medicine residency training was completed at David Grant Medical Center at Travis Air Force Base, California. Following residency, he was a staff internist at Elmendorf Air Force Base Hospital in Anchorage, Alaska. His cardiology and interventional cardiology fellowships were at the Cleveland Clinic Foundation where he was also Chief Cardiology Fellow. Prior to joining Scripps, Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. He was also the Cardiology Fellowship Director, a clinician-scientist and a staff cardiologist there. In the past, beyond his time in the Air Force, Steve has also been a Global Medical Vice-President for The Medicines Company based in Zurich Switzerland and the Director of Cardiovascular Education and Clinical Research at the University of Kentucky in Lexington. Dr Steinhubl’s research activities have covered a broad range of topics in cardiology with a primary early focus on trials of novel antithrombotic therapies for the treatment and prevention of cardiovascular disease, and more recently on the application of an integrated systems-based approach to the optimal identification, communication and treatment of an individual’s risk for various manifestations of cardiovascular disease. He has been principal investigator or helped lead over a dozen large-scale, international randomized trials and has authored over 200 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.

Dr. Pamarti is an Associate Professor in Electrical Engineering at UCLA. He received his B.Tech. degree from the Indian Institute of Technology, Kharagpur, in electronics and electrical communication engineering, and the M.S. and Ph.D. degrees in electrical engineering from University of California, San Diego. Prior to joining UCLA, he worked with Rambus Inc., where he designed mixed-signal circuits for high-speed electrical interfaces for communication between multiple integrated circuits. Prior to his graduate study, he worked with Hughes Software Systems (1995-1997) developing real-time, embedded software and firmware for a wireless-in-local-loop communication system. He has published over 75 peer-reviewed journal articles and conference presentations.

Dr. DiNello, has a BS degree in Biology from Yale University, a PhD in Biological Chemistry from Harvard University and more than 25 years of experience in the diagnostics industry. While a Chiron Corporation, Dr. DiNello led the group that developed the first Hepatitis C ELISA test and transferred the test to Chiron's business partner,Ortho Diagnostics Systems, for manufacturing and marketing. After Chiron Dr. DiNello was a founder of Praxsys Biosystems, the predecessor of ReLIA Diagnostic systems which manufactured and marketed cardiac marker tests in China. While at ReLIA, Dr. DiNello directed the development of lateral flow tests for the cardiac markers: Troponin I, NT-proBNP, D-Dimer, Heart Fatty Acid Binding Protein and Myoglobin. Immediately prior to joining FemtoDx, Dr DiNello led a group which developed a number of lateral flow diagnostic tests at Silver Lake Research. Among them were tests for canine and human bacteriuria. Dr DiNello also headed the group which developed HemoType SC™, a test designed to detect Hemoglobin sickle cell disease and carriers of the sickle cell trait, in low resource use settings, with no specialized equipment. Dr DiNello is listed as an inventor on several diagnostics related patents and has recently been an author of scientific publications describing the detection of bacteria in human urine and the detection of Hemoglobin S and Hemoglobin C with the HemoTypeSC™ test.